Hepatocellular carcinoma (HCC) is the most common primary liver tumor in adults, and the fourth leading cause of cancer-related deaths worldwide. While surgical and ablative therapies remain the standard of care in early localized disease, late presentation with advanced stages of disease, impaired hepatic function, or local recurrence following surgical resection preclude operative management as the sole treatment modality in a subgroup of patients. As such, systemic therapies, namely immunotherapy, have become an integral part of the HCC treatment algorithm over the past decade. While agents, such as atezolizumab/bevacizumab, have well-established roles as first-line systemic therapy in intermediate- and advanced-stage HCC, the role of immunotherapy in disease amenable to surgical management continues to evolve. In this review, we will discuss the current evidence and aggregate impact of immunotherapy in the context of HCC amenable to surgical management, including its application in the neoadjuvant and adjuvant settings.
肝细胞癌（HCC）是成人中最常见的原发性肝脏肿瘤，也是全球癌症相关死亡的第四大原因。尽管手术和消融治疗仍是早期局限性病变的标准治疗方案，但部分患者因疾病晚期就诊、肝功能受损或手术切除后局部复发，使得单纯手术治疗无法作为其唯一治疗方式。因此，在过去十年中，全身性治疗（特别是免疫治疗）已成为肝细胞癌综合治疗方案的重要组成部分。尽管阿特珠单抗/贝伐珠单抗等药物已明确作为中晚期肝细胞癌的一线全身治疗方案，但免疫治疗在适合手术治疗的肝细胞癌中的作用仍在不断发展。本综述将探讨免疫治疗在适合手术治疗的肝细胞癌中的现有证据及综合影响，包括其在新辅助和辅助治疗中的应用。
Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma
肿瘤(癌症)患者之家